Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Law Custodial Inc. filed a Schedule 13G reporting beneficial ownership of 1,409,167 ordinary shares of Dare Bioscience, Inc., representing approximately 15.9% of the 8,871,155 shares outstanding used for the calculation. The filing states the shares were not acquired to change or influence control and that 795,271 of the shares are held as trustee with sole voting and dispositive power. The reporting person is organized in Samoa with a principal address in Hong Kong and the signature is dated 10/06/2025. This ownership level exceeds 5% and must be disclosed under the Exchange Act.
MarDee Haring-Layton, identified as an officer (Chief Accounting Officer) and director of Dare Bioscience, Inc. (DARE), was granted an employee stock option for 57,000 shares on 09/04/2025 at an exercise price of $2.13. The Form 4 reports the options as beneficially owned directly following the grant, totaling 57,000 shares. The explanatory note states the option is a retention award that vests and becomes exercisable on 09/04/2027, unless certain performance criteria are met earlier, and the table indicates an expiration date of 09/04/2035. The Form is signed by the reporting person on 09/04/2025.
Daré Bioscience, Inc. furnished a new corporate presentation dated September 2, 2025, as Exhibit 99.1 to a current report. The company plans to use this presentation in meetings with securities market participants and others starting on that date.
A copy of the presentation is expected to be made available in the Investors section of Daré Bioscience’s website, on the “Presentations, Events & Webcasts” page under “Presentations.” The company notes that the presentation and the related disclosure are being furnished under Regulation FD and are not considered filed for liability purposes under the Exchange Act or automatically incorporated into other SEC filings.